Cellectar Biosciences Inc., a Madison-based company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, announced that the European Medicines Agency has adopted a positive opinion for CLR 131 orphan designation for Cellectar’s treatment for Waldenstrom’s Macroglobulinemiam, a rare blood cancer.
The “orphan drug” designation is given to medicinal products that are deemed to provide a clinically relevant advantage or make a major contribution to patient care with a disease that is life-threatening or chronically debilitating and where the prevalence of the condition in the EU is less than five in 10,000 persons.
